HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Proposes Early Detection System For CFSAN-Regulated Products

This article was originally published in The Tan Sheet

Executive Summary

CFSAN says the program would involve a center-wide, coordinated and systematic effort to identify and then move signals about contaminants, through a review, management and follow-up process. The process could result in an early response by FDA and other agencies to potentially hazardous chemical threats.

You may also be interested in...



Gaps In Spiked Supplement Net Could Shrink With Non-Targeted Screening

FDA plans to deploy testing technology that casts a wider net than its existing targeted adulterant tests, intending to catch product that may be tainted with as-yet-unknown adulterants.

Supplement Ingredient Suppliers Should Prepare For Food HACCP Regs

The exemption Congress gave dietary supplement manufacturers from the hazard analysis and critical control points regulations for food products does not extend to ingredient suppliers, experts say.

Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD

A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124340

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel